MedTrace Logo

Methylation Patterns of the NUPR1, MGMT, NDRG2, and GLI1 Genes and Their Impact on Therapeutic Outcome of GBM Patients

NCT06538428 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2024-08-05

No results posted yet for this study

Summary

The study aimed to investigate the role of promoter methylation of MGMT, NUPR1, NDRG2, and GLI1 genes in glioblastoma multiforme (GBM) patients. Tissue samples were collected from GBM patients and individuals with non-neurooncological diseases (NND). The methylation status of the four genes was analyzed, and the clinical characteristics and survival of GBM patients were evaluated.

Conditions

Interventions

GENETIC

DNA methylation profiling

measurement of methylation levels of MGMT, NUPR1,NDRG2,and GLI1 gene

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Nadia Hamdy, PhD · Professor of Biochemistry, Biochemistry Dept., Faculty of Pharmacy, ASU

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2022-10-01
Completion
2022-12-09

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06538428 on ClinicalTrials.gov